Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
Sign Up to like & getrecommendations! Published in 2022 at "Antiviral Research"
DOI: 10.1016/j.antiviral.2022.105252
Abstract: We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524, molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor nirmatrelvir against the ancestral SARS-CoV2 strain and the five variants… read more here.
Keywords: concern; molnupiravir nirmatrelvir; nirmatrelvir remain; variants concern ... See more keywords
PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13292
Abstract: The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite… read more here.
Keywords: ent1 ent2; remdesivir molnupiravir; remdesivir; 07321332 nirmatrelvir ... See more keywords
The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02395-21
Abstract: Recently, Remdesivir and Molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. ABSTRACT Recently, remdesivir and molnupiravir… read more here.
Keywords: signaling pathways; reactivation; herpesvirus; intracellular signaling ... See more keywords